Cryo-EM methods are beginning to shed light on the structures of HIV intasomes and how INSTIs bind, revealing how small changes in the integrase active site can have significant implications for drug binding. This work has implications for expanding effective treatments available for HIV-infected individuals.
In a recent webinar, Dr. Dmitry Lyumkis from the Salk Institute discussed how the virus’s ability to integrate its genome into host DNA is vulnerable to inhibition and how new technology is advancing high-resolution structural studies. He also discussed how cryo-EM structure-based drug design can help combat the global HIV epidemic.
If you missed the webinar, watch it on-demand now.
Learn more about Thermo Fisher Scientific's cryo-EM workflow solutions.